文献速递妇科

症状性子宫平滑肌瘤手术前后治疗的临床与患者报告结局:TRUST 随机临床试验 12 个月随访回顾,比较腹腔镜射频消融与子宫肌瘤剔除术

Clinical and Patient Reported Outcomes of Pre- and Postsurgical Treatment of Symptomatic Uterine Leiomyomas: A 12-Month Follow-up Review of TRUST, a Surgical Randomized Clinical Trial Comparing Laparoscopic Radiofrequency Ablation and Myomectomy.
PubMed 文献 · J Minim Invasive Gynecol · 2022-01-24

本研究为 TRUST 随机对照试验的二次分析,纳入 57 例症状性子宫平滑肌瘤患者,随机接受腹腔镜射频消融(LAP-RFA,n=30)或子宫肌瘤剔除术(n=27),随访 12 个月。结果显示两组症状均显著改善,LAP-RFA 组住院时间、恢复工作及正常活动时间更短,术后 3 个月住院率更低。作者认为 LAP-RFA 是安全有效的保留子宫的替代方案。

要点

  • 两组术后 3 和 12 个月症状均显著改善,组间改善程度相似。
  • LAP-RFA 组住院时间 8.0±5.7 小时,显著短于肌瘤剔除组的 18.8±14.6 小时(p<.05)。
  • LAP-RFA 组恢复工作时间和正常活动时间均显著短于肌瘤剔除组。

核心结论

  • 12 个月随访结果提示,LAP-RFA 是安全、有效、保留子宫的替代方案,可用于治疗子宫平滑肌瘤。
  • LAP-RFA 总体医疗资源使用更低,包括术后住院率更低和住院时间更短。
  • 作者认为在临床实践中,LAP-RFA 是治疗子宫平滑肌瘤有前景的方法。

研究设计与样本

  • 本研究为 TRUST 美国试验的二次分析,TRUST 为上市后随机、多中心、纵向、对照试验。
  • 共 57 例症状性子宫平滑肌瘤患者随机分配至 LAP-RFA 组(n=30)或子宫肌瘤剔除术组(n=27)。
  • 术后随访 12 个月,主要结局为子宫肌瘤症状减轻和患者报告结局评分改善。

主要发现

  • 两组术后 3 和 12 个月子宫肌瘤症状均显著改善,组间改善程度相似。
  • LAP-RFA 组和肌瘤剔除组从基线至术后 12 个月子宫肌瘤症状每月显著降低分别为 72% 和 85%。
  • 两组所有患者报告结局评分随时间均显著改善。
  • 术后 3 和 12 个月,LAP-RFA 组住院患者百分比分别比腹腔镜肌瘤剔除组低 74% 和 49%,其中 3 个月差异有统计学意义。
  • LAP-RFA 组住院时间显著短于肌瘤剔除组(8.0±5.7 小时 vs 18.8±14.6 小时;p<.05);医生建议恢复工作前休假时间显著更短(10.3±5.1 天 vs 14.5±5.4 天;p<.05);恢复正常活动总天数显著更少(16.3±15.2 天 vs 26.5±15.9 天;p<.05)。

临床怎么用

  • 作者认为 LAP-RFA 是治疗子宫平滑肌瘤有前景的方法。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: The objective of this study was to determine the efficacy, safety, and healthcare resource use of laparoscopic radiofrequency ablation (LAP-RFA) compared with myomectomy in patients with symptomatic uterine leiomyomas (ULs). DESIGN: This was a secondary analysis of the original postmarket randomized, multicenter, longitudinal, comparative TRUST (Treatment Results of Uterine Sparing Technologies) United States trial in patients with symptomatic ULs. After the procedure, subjects were followed over a 12-month period. SETTING: Multicenter trial, including hospitals with or without an academic affiliation, surgery centers, and fertility centers performing outpatient procedures for uterine myomas. PARTICIPANTS: A total of 57 patients were randomized to either LAP-RFA (n = 30) or myomectomy (n = 27). INTERVENTIONS: LAP-RFA or myomectomy (laparoscopic or abdominal). MEASUREMENTS AND MAIN RESULTS: The main outcome measures of this study were part of the secondary outcomes of the original TRUST trial. The primary outcome of this study was the reduction of UL symptoms and the improvement in patient-reported outcomes scores over time. Secondary outcomes included postprocedure hospitalization, length of stay, complications, reinterventions, and recovery time. There was a significant improvement in UL symptoms at 3 and 12 months after the procedure within each treatment group, and these improvements were similar between treatment groups. There was a significant reduction in UL symptoms per month between baseline and 12-months after the procedure for both LAP-RFA and myomectomy of 72% and 85%, respectively. A significant improvement was seen in all patient-reported outcomes scores over time for both groups. At 3 and 12 months after the procedure, the percentages of patients who were hospitalized in the LAP-RFA group were 74% and 49% lower than those of patients in the laparoscopic myomectomy group, respectively, with the 3-month difference being statistically significant. The length of hospital stay was significantly shorter in the LAP-RFA group compared with the myomectomy group (8.0 ± 5.7 hours vs 18.8 ± 14.6 hours; p < .05). Doctors recommended taking significantly less time off before returning to work for the patients in the LAP-RFA group compared with those in the myomectomy group (10.3 ± 5.1 days vs 14.5 ± 5.4 days; p < .05). The total number of days until back to normal activity was significantly lower in the LAP-RFA group compared with the myomectomy group (16.3 ± 15.2 days vs 26.5 ± 15.9 days; p < .05). CONCLUSION: The results from this 12-month follow-up study suggest that LAP-RFA is a safe, effective, uterine-sparing alternative to laparoscopic myomectomy in the treatment of ULs. These data points build on previously published studies showing that LAP-RFA has lower healthcare resource use overall, including lower postprocedure hospitalization rate and shorter length of stay. In clinical practice, LAP-RFA is a promising treatment approach to ULs for women.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Yu S, Bhagavath B, Shobeiri SA, et al. Clinical and Patient Reported Outcomes of Pre- and Postsurgical Treatment of Symptomatic Uterine Leiomyomas: A 12-Month Follow-up Review of TRUST, a Surgical Randomized Clinical Trial Comparing Laparoscopic Radiofrequency Ablation and Myomectomy. J Minim Invasive Gynecol. 2022. PMID: 35085837. doi:10.1016/j.jmig.2022.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。